The U.S. Food and Drug Administration (FDA) has approved Tandem Mobi's insulin pump app for Android smartphones, allowing broader access for users. This marks a significant advancement for Tandem Diabetes Care, offering Android users a way to manage their diabetes via smartphones.
Expanded Platform Access
Previously limited to Apple users, the Tandem Mobi insulin pump system can now be used with Android devices starting in December 2025. The integration, facilitated through Control-IQ+ technology, enhances blood glucose management by automatically adjusting insulin doses. This connection is pivotal in broadening the user base.
Devices initially supported include Google Pixel models 6 through 10 and Samsung Galaxy S21 through S25. A nationwide rollout is expected by early 2026, signaling a new phase of accessibility in diabetes care.
Technological Advancements
The Tandem Mobi system is a compact, wearable device that interfaces with compatible smartphones. By receiving continuous blood glucose data, it streamlines diabetes management. The system's Control-IQ+ technology has demonstrated potential for improved blood sugar outcomes, some as early as the first day of use.
This advancement connects to the Tandem Source platform, facilitating communication with healthcare providers and reducing the need for traditional medical devices. As a result, users can experience a more seamless and integrated approach to their healthcare.
Market Implications
The FDA approval of the Android app addresses a critical gap in the market. By allowing the Tandem Mobi system to operate on Android, Tandem Diabetes Care can reach a broader demographic, providing a significant tailwind for business growth. The rollout starts with a limited release in December and expands nationwide in early 2026, likely boosting Tandem's market position.
